Sugar-sweetened beverage intake increases multiple dyslipidemia features, CVD risk

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-02-21 14:30 GMT   |   Update On 2023-02-21 14:30 GMT

A new study by Danielle Haslam and team found that higher sugar-sweetened beverage (SSB) intake was connected to developing various dyslipidemia traits that have been linked to increased cardiometabolic risk in the US adults. The findings of this study were published in The Journal of Nutrition.Prospective cohort studies have discovered a link between the use of sugar-sweetened beverages...

Login or Register to read the full article

A new study by Danielle Haslam and team found that higher sugar-sweetened beverage (SSB) intake was connected to developing various dyslipidemia traits that have been linked to increased cardiometabolic risk in the US adults. The findings of this study were published in The Journal of Nutrition.

Prospective cohort studies have discovered a link between the use of sugar-sweetened beverages (sodas and fruit drinks) and dyslipidemia. There is minimal evidence relating SSB intake to developing dyslipidemia characteristics such as remnant-like particle (RLP), lipoprotein particle size, and apolipoprotein concentrations. As a result, this study was carried out to investigate the relationship between SSB intake and apolipoprotein, plasma lipoprotein cholesterol, and lipoprotein particle size levels in US adults.

The Framingham Offspring Study and the Women's Health Study were studied by the researchers. Plasma LDL cholesterol, TG, HDL cholesterol, apoB, apoA1, and non-HDL cholesterol concentrations, as well as total cholesterol:HDL cholesterol ratio and apoB:apoA1 ratio, were measured in both cohorts; apolipoprotein E, apolipoprotein C3, RLP-TG, and RLP cholesterol (RLP-C) concentrations were measured in the FOS only. Nuclear magnetic resonance signals for lipoprotein particle subclass concentrations were used to compute particle sizes. Data from food frequency questionnaires were used to estimate SSB intake. The relationships between SSB intake and all lipoprotein and apoprotein measurements were also examined in linear regression models that controlled for confounding variables such lifestyle, food, and conventional lipoprotein risk factors.

The key findings of this study were:

SSB intake was related to LDL cholesterol, apoB, TG, RLP-TG, RLP-C, and non-HDL cholesterol concentrations, as well as total cholesterol:HDL cholesterol and apoB:apoA1 ratios, but not to HDL cholesterol or apoA1 concentrations.

SSB users had smaller LDL-P and HDL-P sizes, lower concentrations of big LDL-Ps and medium HDL-Ps, and greater concentrations of small LDL-Ps, small HDL-Ps, and large TRL-Ps after controlling for established lipoprotein risk factors.

According to these results, increased SSB intake is connected to greater plasma lipoprotein concentrations that have been linked to negative cardiometabolic outcomes, including classic and newer measures of apolipoprotein, lipoprotein cholesterol, and lipoprotein particle concentrations. These findings imply a possible mechanism by which SSB consumption may raise the risk of cardiometabolic diseases: variations in lipoprotein particle sizes.

Reference: 

Haslam, D. E., Chasman, D. I., Peloso, G. M., Herman, M. A., Dupuis, J., Lichtenstein, A. H., Smith, C. E., Ridker, P. M., Jacques, P. F., Mora, S., & McKeown, N. M. (2022). Sugar-Sweetened Beverage Consumption and Plasma Lipoprotein Cholesterol, Apolipoprotein, and Lipoprotein Particle Size Concentrations in US Adults. In The Journal of Nutrition (Vol. 152, Issue 11, pp. 2534–2545). Elsevier BV. https://doi.org/10.1093/jn/nxac166

Tags:    
Article Source : The Journal of Nutrition

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News